ReviewJournal of surgical oncology2026
MicroRNA Expression in Breast Cancer Patients, an Integrative Review.
Review in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fluorescence encoding technology based tetrahedral nano-string for logic identification of breast cancer cells.Materials today. Bio · 2026Article
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
- MicroRNA Expression in Breast Cancer Patients, an Integrative Review.Journal of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This integrative review examines the differential expression of miRNAs in breast cancer patients across various disease stages. Through analysis of 42 articles published between 2005 and 2023, the review identifies multiple miRNAs with significant diagnostic, prognostic, and predictive potential in breast cancer management. These small noncoding RNAs, accessible through liquid biopsy, demonstrate notable potential for early detection, molecular subtype classification, treatment response prediction, and relapse monitoring. The findings highlight miRNAs as promising biomarkers for precision medicine approaches, potentially enhancing clinical decision-making and improving patient outcomes. Notably, miRNAs such as miR-21, miR-155, and members of the miR-200 family show consistent associations with clinical parameters across multiple studies. The accessibility of miRNAs in blood and other body fluids, combined with their stability and specificity, positions them as valuable tools that could complement conventional diagnostic methods and support more personalized treatment strategies in breast cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.